PepGen Ltd (PEPG) - Total Assets
Based on the latest financial reports, PepGen Ltd (PEPG) holds total assets worth $173.91 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PEPG net assets for net asset value and shareholders' equity analysis.
PepGen Ltd - Total Assets Trend (2019–2025)
This chart illustrates how PepGen Ltd's total assets have evolved over time, based on quarterly financial data.
PepGen Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
PepGen Ltd's total assets of $173.91 Million consist of 86.8% current assets and 13.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how PepGen Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of PepGen Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PepGen Ltd's current assets represent 86.8% of total assets in 2025, a decrease from 90.0% in 2019.
- Cash Position: Cash and equivalents constituted 34.8% of total assets in 2025, down from 83.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
PepGen Ltd Competitors by Total Assets
Key competitors of PepGen Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
PepGen Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.94 | 7.41 | 1.87 |
| Quick Ratio | 11.94 | 7.41 | 1.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $138.32 Million | $107.06 Million | $4.54 Million |
PepGen Ltd - Advanced Valuation Insights
This section examines the relationship between PepGen Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.78 |
| Latest Market Cap to Assets Ratio | 0.64 |
| Asset Growth Rate (YoY) | 15.3% |
| Total Assets | $173.91 Million |
| Market Capitalization | $111.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values PepGen Ltd's assets below their book value (0.64x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: PepGen Ltd's assets grew by 15.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PepGen Ltd (2019–2025)
The table below shows the annual total assets of PepGen Ltd from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $173.91 Million | +15.26% |
| 2024-12-31 | $150.88 Million | +5.47% |
| 2023-12-31 | $143.05 Million | -34.21% |
| 2022-12-31 | $217.44 Million | +51.38% |
| 2021-12-31 | $143.64 Million | +1249.76% |
| 2020-12-31 | $10.64 Million | +153.80% |
| 2019-12-31 | $4.19 Million | -- |
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatm… Read more